Are GLPs Going to the Dogs?

GLP-1s rewrote the rules of human medicine. Before animal-health

innovators chase the same playbook, the species-by-species math

tells a very different story.

GLP-1 receptor agonists have become one of the most commercially disruptive drug

classes in modern healthcare. Combined sales of semaglutide and tirzepatide alone

cleared roughly $52 billion in 2024, and Wall Street analysts now put the human obesity

and cardiometabolic GLP-1 market on a path toward $150–$185 billion by the early 2030s. Naturally, innovators are asking the same question about the veterinary world: can animal health be next?

The tempting, oversimplified leap

The temptation is to assume that success in humans can be directly replicated in animals. That's exactly where many development teams get into trouble. The biology that made semaglutide and tirzepatide blockbusters in people, appetite suppression through incretin signaling, doesn't map onto every species the same way, and the commercial conditions that support a $1,000-a-month human prescription rarely exist in veterinary medicine.

There is real biological groundwork here. Peer-reviewed research has already shown that GLP-1 and GIP pathways are conserved enough in dogs and cats that semaglutide and tirzepatide produce meaningful weight loss in preclinical models, and at least one GLP-1 implant for overweight cats is now in active veterinary study. Roughly 56–61% of U.S. cats and around half of U.S. dogs are classified as overweight or obese, so the clinical need is not in question. What's in question is which species, if any, can support a viable product.

Animal health is not one market. It's a collection of species-

specific markets, each with its own biology, clinical challenges,

customer motivations, and economics.

Why "the dog" isn't a market, it's five markets

A Chihuahua owner, a working cutting-horse trainer, and a dairy producer are not the same customer with different species focus. They have different willingness to pay, different regulatory pathways, different delivery-method tolerances, and completely different definitions of a successful outcome. That's the species readiness matrix below: the same molecule can be a breakthrough in one market and a dead end in another.

The real filter innovators need

The right question isn't "will GLP-ls work in animals?" Preliminary science says yes, at least in cats and dogs. The right question is whether a given species has the disease prevalence, owner willingness to pay, feasible delivery method, and regulatory runway to support a real product, not just a research finding. Right now, cats offer the clearest early opportunity: high obesity prevalence, a diabetes link, and an implant format that sidesteps the feeding routines pet owners are reluctant to change. Dogs are close behind, complicated differences in breed, sizes and dosing needs. Horses have high clinical need to treat obesity and associated metabolic disease, but side effects from GLP MOA could cause deadly GI stasis, while there is no need for weight loss in livestock. The interplay between drug, species, and market make commercialization complex.

Is your pudgy pooch ready for a GLP-1? Probably not this year. Is your cat? That's the market to watch first..

For animal health innovators: before greenlighting a GLP-1 program, map the species-specific customer, not just the species-specific biology. The molecule is rarely the hard part.